69th Day Of Lockdown

Maharashtra65168280812197 Tamil Nadu2024611313157 Delhi173877846398 Gujarat1635692321007 Rajasthan83654855184 Madhya Pradesh78914444343 Uttar Pradesh77014651213 West Bengal48131775302 Andhra Pradesh3461228960 Bihar3359120915 Karnataka292299749 Telangana2499141277 Jammu and Kashmir234190828 Punjab2197194942 Odisha17239779 Haryana172194019 Kerala120957510 Assam9361044 Uttarakhand493794 Jharkhand4621914 Chhatisgarh4471021 Chandigarh2891994 Tripura2711720 Himachal Pradesh223634 Goa70420 Manipur6060 Puducherry57230 Nagaland3600 Meghalaya27121 Arunachal Pradesh310 Mizoram110 Sikkim100
Lifestyle Health and Wellbeing 08 Oct 2017 Antifungal drug to c ...

Antifungal drug to cure life threatening fungal infections developed

ANI
Published Oct 8, 2017, 10:52 am IST
Updated Oct 8, 2017, 10:52 am IST
This is the first new class of antifungal agent to be discovered in the last three decades.
This is the first new class of antifungal agent to be discovered in the last three decades. (Photo: Pixabay)
 This is the first new class of antifungal agent to be discovered in the last three decades. (Photo: Pixabay)

Invasive fungal infections are known to be really lethal.

These infections mostly occur in the context of leukemia and bone marrow transplantation and often in young patients with otherwise curable disease.

 

The researchers have now found a new drug which may help in the treatment of life threatening fungal infections such as aspergillosis.

The scientists have characterised the biochemical and physiologic effects (pharmacodynamics) of F901318, which is the lead compound of the new class of drugs termed the 'orotomides'.

The 'orotomides', discovered by F2G Limited, have a novel mechanism of action which is the specific biochemical interaction through which a drug substance produces its pharmacological effect.

This is the first new class of antifungal agent to be discovered in the last three decades.

Study's lead author, Professor William Hope from the University's Antimicrobial Pharmacodynamics and Therapeutics (APT) Group, said, "Antifungal resistance represents a major global clinical challenge. This study provides the necessary information to enable F901318 to be developed for clinical use."

The study was published in journal mBio.

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT